CRISPR THERAPEUTICS AG Other Noncash Income (Expense)
CRISPR THERAPEUTICS AG (CRSP) reported Other Noncash Income (Expense) of $4.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-03
- CRISPR THERAPEUTICS AG other noncash income (expense) for the quarter ending 2026-06-30 was $13.56M, a 85.08% increase year-over-year.
- CRISPR THERAPEUTICS AG other noncash income (expense) for the quarter ending 2026-03-31 was -$8.80M.
- CRISPR THERAPEUTICS AG other noncash income (expense) for the quarter ending 2025-12-31 was $8.31M, a 45.14% decline year-over-year.
- CRISPR THERAPEUTICS AG other noncash income (expense) for the quarter ending 2025-09-30 was $10.14M, a 47.01% increase year-over-year.
- CRISPR THERAPEUTICS AG other noncash income (expense) for fiscal 2025 was $23.53M, a 39.08% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG other noncash income (expense) for fiscal 2024 was $38.62M, a 133.41% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG other noncash income (expense) for fiscal 2023 was $16.55M.
- CRISPR THERAPEUTICS AG other noncash income (expense) for fiscal 2022 was -$12.47M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $4.76M 10-Q · filed 2026-08-03 | $13.08M derived: sum of 3 quarters · filed 2026-08-03 | $23.22M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$8.80M 10-Q · filed 2026-05-04 | -$486.00K derived: sum of 2 quarters · filed 2026-05-04 | $9.65M derived: sum of 3 quarters · filed 2026-05-04 | $16.98M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $18.45M derived: sum of 2 quarters · filed 2026-02-12 | $25.78M derived: sum of 3 quarters · filed 2026-08-03 | $23.53M 10-K · filed 2026-02-12 |
| 2025-09-30 | $10.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $17.47M derived: sum of 2 quarters · filed 2026-08-03 | $15.21M 10-Q · filed 2025-11-10 | $30.37M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $5.08M 10-Q · filed 2026-08-03 | $20.23M derived: sum of 3 quarters · filed 2026-08-03 | $27.13M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$2.25M 10-Q · filed 2026-05-04 | $12.90M derived: sum of 2 quarters · filed 2026-05-04 | $19.80M derived: sum of 3 quarters · filed 2026-05-04 | $27.98M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $22.05M derived: sum of 2 quarters · filed 2026-02-12 | $30.23M derived: sum of 3 quarters · filed 2026-02-12 | $38.62M 10-K · filed 2026-02-12 |
| 2024-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $15.08M derived: sum of 2 quarters · filed 2025-11-10 | $23.46M 10-Q · filed 2025-11-10 | $28.23M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $8.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $16.57M 10-Q · filed 2025-08-04 | $21.33M derived: sum of 3 quarters · filed 2026-02-12 | $27.49M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $8.38M 10-Q · filed 2025-05-06 | $13.15M derived: sum of 2 quarters · filed 2026-02-12 | $19.31M derived: sum of 3 quarters · filed 2026-02-12 | $23.96M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $10.93M derived: sum of 2 quarters · filed 2026-02-12 | $15.58M derived: sum of 3 quarters · filed 2026-02-12 | $16.55M 10-K · filed 2026-02-12 |
| 2023-09-30 | $6.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $10.81M derived: sum of 2 quarters · filed 2024-11-05 | $11.78M 10-Q · filed 2024-11-05 | $11.56M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $4.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $5.62M 10-Q · filed 2024-08-05 | $5.40M derived: sum of 3 quarters · filed 2025-02-11 | $2.82M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $969.00K 10-Q · filed 2024-05-08 | $750.00K derived: sum of 2 quarters · filed 2025-02-11 | -$1.83M derived: sum of 3 quarters · filed 2025-02-11 | -$5.40M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$2.80M derived: sum of 2 quarters · filed 2025-02-11 | -$6.37M derived: sum of 3 quarters · filed 2025-02-11 | -$12.47M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$6.15M derived: sum of 2 quarters · filed 2023-11-06 | -$12.25M 10-Q · filed 2023-11-06 | -$16.94M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$9.67M 10-Q · filed 2023-08-07 | -$14.36M derived: sum of 3 quarters · filed 2024-02-21 | -$19.36M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$6.10M 10-Q · filed 2022-05-09 | -$10.79M derived: sum of 2 quarters · filed 2024-02-21 | -$15.79M derived: sum of 3 quarters · filed 2024-02-21 | -$18.14M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$9.69M derived: sum of 2 quarters · filed 2024-02-21 | -$12.04M derived: sum of 3 quarters · filed 2024-02-21 | -$14.11M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$7.36M derived: sum of 2 quarters · filed 2022-11-01 | -$9.42M 10-Q · filed 2022-11-01 | -$10.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$4.42M 10-Q · filed 2022-08-08 | -$5.29M derived: sum of 3 quarters · filed 2023-02-21 | -$5.38M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$2.06M 10-Q · filed 2022-05-09 | -$2.94M derived: sum of 2 quarters · filed 2023-02-21 | -$3.03M derived: sum of 3 quarters · filed 2023-02-21 | -$3.03M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$878.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$968.00K derived: sum of 2 quarters · filed 2023-02-21 | -$967.00K derived: sum of 3 quarters · filed 2023-02-21 | -$1.86M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$89.00K derived: sum of 2 quarters · filed 2021-11-03 | -$979.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$889.00K 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | -$890.00K 10-Q · filed 2021-04-27 | |||
| 2018-12-31 | $169.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |